Apricell Biotechnology Inc. is dedicated to reducing the attrition rate of new cancer drugs in clinical trials.  In collaboration with the University, Apricell has developed a novel Organoid-on-a-Plate technology that opens up multiple opportunities for researchers and oncologists all the way from basic research and drug testing to advanced patient management